scholarly journals Prognosis and safety of radium‐223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration‐resistant prostate cancer: Real‐world data of Japanese patients

BJUI Compass ◽  
2020 ◽  
Author(s):  
Yasuhide Miyoshi ◽  
Masato Yasui ◽  
Sohgo Ttsutsumi ◽  
Takashi Kawahara ◽  
Ko‐ichi Uemura ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Real World ◽  
Japanese Patients ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Real World Data ◽  
World Data ◽  
Castration Resistant ◽  
Radium 223

A retrospective analysis of treatment patterns in metastatic castration-resistant prostate cancer patients treated with radium-223.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 180-180 ◽  
Author(s):  
A. Oliver Sartor ◽  
Sreevalsa Appukkuttan ◽  
Ronald E. Aubert ◽  
Jeffrey Weiss ◽  
Joy Wang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Real World ◽  
Pilot Trial ◽  
Clinical Trial Data ◽  
Castration Resistant Prostate Cancer ◽  
Real World Data ◽  
Data Set ◽  
World Data ◽  
Castration Resistant ◽  
Radium 223

180 Background: Radium-223 (RA-223) is the first FDA approved targeted alpha therapy that significantly improves overall survival (OS) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) with symptomatic bone metastases. There is limited real world data describing RA-223 current use. Methods: A retrospective patient chart review was done of men who received at least 1 cycle of Ra-223 for mCRPC in 10 centers throughout the US (4 academic, 6 private practices). All pts had a minimum follow-up of 4 months, or placed in hospice or death. Descriptive analyses for clinical characteristics and treatment outcomes were performed. Results: Among the 200 pts (mean age-73.6 years, mean Charlson comorbidity index-6.9) RA-223 was initiated on average 1.6 years from mCRPC diagnosis (first line use (1L)=38.5%, 2L=31.5% and ≥3L=30%). 78% completed 5-6 cycles of RA-223 with mean therapy duration of 4.2 months. Among all pts, 43% received RA-223 as monotherapy (no overlap with other mCRPC therapies) while 57% had combination therapy with either abiraterone or enzalutamide. Median OS following RA-223 initiation was 21.2 months (95% CI 19.6- 29.2). Table provides the RA-223 utilization by type of clinical practice. Conclusions: Utilization of RA-223 in this real world data set was distinct from clinical trial data. Most patients received RA-223 in combination with abiraterone or enzalutamide, therapies that were unavailable when the pilot trial was conducted. Median survival was 21.2 months. Real world use of RA-223 has evolved as newer agents have become FDA approved in bone-metastatic CRPC. Academic and community patterns of practice were more similar than distinct. [Table: see text]

Efficacy of abiraterone acetate in castration‐resistant metastatic prostate cancer: A real‐world data analysis

2020 ◽  
Author(s):  
Abdilkerim Oyman ◽  
Mustafa Başak ◽  
Melike Özçelik ◽  
Deniz Tataroğlu Özyükseler ◽  
Selver Işık ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Data Analysis ◽  
Real World ◽  
Metastatic Prostate Cancer ◽  
Abiraterone Acetate ◽  
Real World Data ◽  
World Data ◽  
Castration Resistant

scholarly journals Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer

2020 ◽  
Vol 23 (4) ◽  
pp. 680-688
Author(s):  
Neal Shore ◽  
Celestia S. Higano ◽  
Daniel J. George ◽  
Cora N. Sternberg ◽  
Fred Saad ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Real World ◽  
Incidence Rates ◽  
Castration Resistant Prostate Cancer ◽  
Real World Data ◽  
Combination Treatments ◽  
Castration Resistant ◽  
Radium 223 ◽  
Pathologic Fractures ◽  
Health Database

Abstract Background In this study, we evaluated real-world data on radium-223 plus abiraterone/prednisone or enzalutamide. Previously, the ERA 223 trial (NCT02043678) demonstrated increased fracture risk with concurrent treatment with radium-223 and abiraterone plus prednisone/prednisolone in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods We used the Flatiron Health database to perform a retrospective study of patients with mCRPC treated with radium-223. Treatment with radium-223 plus abiraterone/prednisone or enzalutamide was defined as concurrent if both drugs started within 30 days of one another, or layered when the second drug started ≥30 days after the first. The index date was defined as the day of the first radium-223 dose. Outcome measures included symptomatic skeletal events (SSEs), overall survival (OS), and patterns of treatments received. Results Of the 625 patients treated with radium-223, 22% received it together with abiraterone/prednisone and 27% with enzalutamide. When these agents were combined, they were often initiated in a layered fashion (73% layered, 23% concurrent). Prior or concomitant bone health agents (BHAs) were received by 67% and 55% of patients, respectively. Median follow-up was 9 months. Overall, incidence rates for SSEs and pathologic fractures were 0.35 and 0.11 patients per person-year, respectively. Median OS from mCRPC diagnosis was 28.1 months. Conclusions In this real-world setting, combination treatments with radium-223 and abiraterone/prednisone or enzalutamide were common. These agents were more commonly given in a layered than a concurrent fashion. Incidence rates for SSEs were reduced when BHAs were used; however, BHAs were underutilized.

Sign in / Sign up

Export Citation Format

Share Document